JPWO2022121981A5 - - Google Patents
Info
- Publication number
- JPWO2022121981A5 JPWO2022121981A5 JP2023535475A JP2023535475A JPWO2022121981A5 JP WO2022121981 A5 JPWO2022121981 A5 JP WO2022121981A5 JP 2023535475 A JP2023535475 A JP 2023535475A JP 2023535475 A JP2023535475 A JP 2023535475A JP WO2022121981 A5 JPWO2022121981 A5 JP WO2022121981A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- solvate
- hydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011463704 | 2020-12-11 | ||
| CN202011463704.4 | 2020-12-11 | ||
| PCT/CN2021/136769 WO2022121981A1 (zh) | 2020-12-11 | 2021-12-09 | 新型喜树碱衍生物、含其的组合物和其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023552610A JP2023552610A (ja) | 2023-12-18 |
| JPWO2022121981A5 true JPWO2022121981A5 (enExample) | 2026-01-16 |
Family
ID=81974225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023535475A Pending JP2023552610A (ja) | 2020-12-11 | 2021-12-09 | 新規カンプトテシン誘導体、それを含む組成物およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230416270A1 (enExample) |
| EP (1) | EP4265620A4 (enExample) |
| JP (1) | JP2023552610A (enExample) |
| KR (1) | KR20230118891A (enExample) |
| CN (1) | CN116583526B (enExample) |
| AU (1) | AU2021394411A1 (enExample) |
| CA (1) | CA3200649A1 (enExample) |
| MX (1) | MX2023006751A (enExample) |
| WO (1) | WO2022121981A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024014837A1 (ko) * | 2022-07-11 | 2024-01-18 | 주식회사 피노바이오 | Ddx5 단백질에 결합하는 캄토테신 유도체 및 이의 프로드럭 |
| KR102630719B1 (ko) * | 2022-07-11 | 2024-01-30 | 주식회사 피노바이오 | Ddx5 단백질에 결합하는 캄토테신 유도체 및 이의 프로드럭 |
| AU2024243250A1 (en) * | 2023-04-07 | 2025-10-16 | Changchun Genescience Pharmaceutical Co., Ltd. | Camptothecin derivative, and pharmaceutical composition, preparation method therefor and use thereof |
| WO2025084851A1 (ko) * | 2023-10-19 | 2025-04-24 | (주)셀트리온 | 캄프토테신 유도체를 포함하는 항-c-met 항체-약물 접합체 |
| KR20250057675A (ko) * | 2023-10-19 | 2025-04-29 | (주)셀트리온 | 캄프토테신 유도체를 포함하는 항-Tissue factor 항체-약물 접합체 |
| KR20250057677A (ko) * | 2023-10-19 | 2025-04-29 | (주)셀트리온 | 캄프토테신 유도체를 포함하는 항-Nectin-4 항체-약물 접합체 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3008226B2 (ja) * | 1991-01-16 | 2000-02-14 | 第一製薬株式会社 | 六環性化合物 |
| JP3359955B2 (ja) * | 1992-07-16 | 2002-12-24 | 第一製薬株式会社 | 抗腫瘍剤 |
| DE19640207A1 (de) * | 1996-09-30 | 1998-04-02 | Bayer Ag | Glycokonjugate von modifizierten Camptothecin-Derivaten (A- oder B-Ring-Verknüpfung) |
| JP2000044567A (ja) * | 1998-07-29 | 2000-02-15 | Dai Ichi Seiyaku Co Ltd | 六環性化合物 |
| FI4212552T3 (fi) * | 2014-01-31 | 2025-01-31 | Daiichi Sankyo Co Ltd | Anti-her2-vasta-aine-lääkeainekonjugaatti |
| WO2015155976A1 (ja) * | 2014-04-10 | 2015-10-15 | 第一三共株式会社 | 抗ｈｅｒ２抗体－薬物コンジュゲート |
| US20190330368A1 (en) * | 2016-10-07 | 2019-10-31 | Daiichi Sankyo Company, Limited | Therapy for drug-resistant cancer by administration of anti-her2 antibody/drug conjugate |
| KR20210038904A (ko) * | 2018-07-25 | 2021-04-08 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘쥬게이트의 효과적인 제조 방법 |
| CN119185572A (zh) * | 2018-09-26 | 2024-12-27 | 江苏恒瑞医药股份有限公司 | 依喜替康类似物的配体-药物偶联物其制备方法和应用 |
| MX2021003446A (es) * | 2018-09-30 | 2021-06-15 | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Conjugado analogo del anticuerpo anti-bth3 y exatecan, y uso medicinal del mismo. |
| CN111689980A (zh) * | 2019-05-26 | 2020-09-22 | 四川百利药业有限责任公司 | 一种喜树碱药物及其抗体偶联物 |
| KR20220025861A (ko) * | 2019-06-28 | 2022-03-03 | 상하이 후단-장지앙 바이오-파마슈티컬 컴퍼니 리미티드 | 항체 약물 복합체, 이의 중간체, 제조 방법 및 용도 |
| WO2022171115A1 (zh) * | 2021-02-09 | 2022-08-18 | 微境生物医药科技(上海)有限公司 | 用于adc制备的喜树碱衍生物 |
-
2021
- 2021-12-09 AU AU2021394411A patent/AU2021394411A1/en active Pending
- 2021-12-09 EP EP21902686.1A patent/EP4265620A4/en active Pending
- 2021-12-09 KR KR1020237022556A patent/KR20230118891A/ko active Pending
- 2021-12-09 JP JP2023535475A patent/JP2023552610A/ja active Pending
- 2021-12-09 CA CA3200649A patent/CA3200649A1/en active Pending
- 2021-12-09 CN CN202180082581.6A patent/CN116583526B/zh active Active
- 2021-12-09 MX MX2023006751A patent/MX2023006751A/es unknown
- 2021-12-09 US US18/039,229 patent/US20230416270A1/en active Pending
- 2021-12-09 WO PCT/CN2021/136769 patent/WO2022121981A1/zh not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024050527A5 (enExample) | ||
| JP2004516314A5 (enExample) | ||
| JP2006501181A5 (enExample) | ||
| RU2005107314A (ru) | Пиримидопроизводные, характеризующиеся антипролиферативной активностью | |
| JP2022081661A5 (enExample) | ||
| JP2002030084A5 (enExample) | ||
| ME00876B (me) | 4"supstituisani-9-deokso-9a-aza-9a-homoeritromicin a derivati | |
| JP2006509749A5 (enExample) | ||
| JP2010540508A5 (enExample) | ||
| JP2008510691A5 (enExample) | ||
| JP2002539128A5 (enExample) | ||
| JPWO2023099592A5 (enExample) | ||
| CA2422375A1 (en) | 3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents | |
| RU98102128A (ru) | Производные бензо[g]хинолина | |
| JP6270848B2 (ja) | ベータ−クロロシクロペンタンの親水性エステルプロドラッグの使用による角膜中央部肥厚の低下 | |
| RU2008152763A (ru) | Применение агонистов каннабиноидного рецептора в качестве индуцирующих гипотермию лекарственных средств для лечения ишемии | |
| JP2005502621A5 (enExample) | ||
| JPWO2021030555A5 (enExample) | ||
| JPH0920659A5 (enExample) | ||
| JP2007507474A5 (enExample) | ||
| JPWO2022121981A5 (enExample) | ||
| JP2004525178A5 (enExample) | ||
| JP2005516898A5 (enExample) | ||
| JPH1087577A5 (enExample) | ||
| RU2010154417A (ru) | Комбинация частичного агониста никотиновых рецепторов и ингибитора ацетилхолинетеразы, содержащая ее фармацетическая композиция, и ее применение в лечении когнитивных расстройств |